Serum hyaluronan as a marker of liver fibrosis in asymptomatic chronic viral hepatitis B

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 59, Issue 5, 1999, Pages 343-347

  Pontinha, N ^a   Pessegueiro, H ^a   Barros, Henrique ^a  

^a University of Porto   (Portugal)

Author keywords

Hyaluronan; Liver fibrosis; Viral hepatitis B (chronic)

Indexed keywords

ALCOHOL; HEPATITIS B SURFACE ANTIGEN; HYALURONIC ACID; MARKER; POLYSACCHARIDE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DISEASE CARRIER; DISEASE SEVERITY; FEMALE; HEPATITIS B; HUMAN; HUMAN TISSUE; INFLAMMATION; LIVER BIOPSY; LIVER DISEASE; LIVER FIBROSIS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RADIOMETRY; SMOKING; TOBACCO;

NICOTIANA TABACUM;

EID: 0032833634     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365519950185535     Document Type: Article

References (24)

1. Laurent TC. Structure of hyaluronic acid. In: Balazs EA, editor. Chemistry and molecular biology of the intercellular matrix. London: Academic Press, 1970: 703-32.
2. Fraser JRE, Laurent TC, Pertoft H, Baxter E. Plasma clearance, tissue distribution and metabolism of hyaluronan injected intravenously in the rabbit. Biochem J 1981; 200: 415-24.
3. Fraser JRE, Laurent TC, Engström-Laurent A, Laurent UBG. Elimination of hyaluronic acid from the blood stream in the human. Clin Exp Pharmacol Physiol 1984; 11: 17-25.
4. Eriksson S, Fraser JRE, Laurent TC, Pertoft H, Smedsrød B. Endothelial cells are a site of uptake and degradation of hyaluronic acid in the liver. Exp Cell Res 1983; 144: 223-8.
5. Engström-Laurent A, Laurent UBG, Lilja K, Laurent TC. Concentration of sodium hyaluronate in serum. Scand J Clin Lab Invest 1985; 45: 497-504.
6. Engström-Laurent A, Lööf L, Nyberg A, Schröder T. Increased serum levels of hyaluronan in liver disease. Hepatology 1985; 5: 638-42.
7. Nyberg A, Engström-Laurent A, Lööf L. Serum hyaluronan in primary biliary cirrhosis - a biochemical marker for progressive liver damage. Hepatology 1988; 8: 142-6.
8. Frébourg T, Delpech B, Bercoff E, Senant J, Bertrand P, Deugnier Y, Bourreille J. Serum hyaluronan in liver diseases: study by enzymoimmunological assay. Hepatology 1986; 6: 392-5.
9. Gibson PR, Fraser JRE, Brown TJ, Finch CF, Jones PA, Colman JC, Dudley FJ. Hemodynamic and liver function predictors of serum hyaluronan in alcoholic liver disease. Hepatology 1992; 15: 1054-9.
10. Plebani M, Giacomini A, Floreani A, Chiaramonte M, Soffiati G, Naccarto R, Burlina A. Biochemical markers of hepatic fibrosis in primary biliary cirrhosis. Res Clin Lab 1990; 20: 269-74.
11. Guéchot J, Poupon RE, Giral P, Balkau B, Giboudeau J, Poupon R. Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. J Hepatol 1994; 20: 388-93.
12. Laurent TC, Laurent UBG, Fraser JRE. Serum hyaluronan as a disease marker. Ann Med 1996; 28: 241-53.
13. Guéchot J, Poupon RE, Poupon R. Serum hyaluronan as a marker of liver fibrosis. J Hepatol 1995; 22 Suppl 2: 103-6.
14. Körner T, Kropf J, Gressner AM. Serum laminin and hyaluronan in liver cirrhosis: markers of progression with high prognostic value. J Hepatology 1996; 25: 684-8.
15. Laurent UBG, Tengblad A. Determination of hyaluronate in biological samples by a specific radioassay. Anal Biochem 1980; 109: 386-94.
16. Tengblad A. Quantitative analysis of hyaluronate in nanogram amounts. Biochem J 1980; 185: 101-5.
17. DeGroot J, Desmet VJ, Gedigk P, Korb G, Popper H, Poulsen H, Scheuer PJ, Schmid M, Thaler H, Uchlinger F. A classification of chronic hepatitis. Lancet 1968; 2: 626-8.
18. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histologic activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
19. Guéchot J, Loria A, Serfaty L, Giral P, Giboudeau J, Poupon R. Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of α-interferon therapy. J Hepatol 1995; 22: 22-6.
20. Murawaki Y, Ikuta Y, Nishimura Y, Koda M, Kawasaki H. Serum markers for connective tissue turnover in patients with chronic hepatitis B and chronic hepatitis C: a comparative analysis. J Hepatol 1995; 23: 145-52.
21. Matsunaga T, Kojima J, Inoue A, Matsumiya K. Serum hyaluronate levels predict responsiveness to interferon alpha therapy in patients with chronic hepatitis C. Clin Chem Acta 1994; 229: 191-5.
22. Yamada M, Fukuda Y, Koyama Y, Nakano I, Urano F, Katano Y, Hayakawa T. Serum hyaluronic acid reflects the effect of interferon treatment on hepatic fibrosis in patients with chronic hepatitis C. J Gastroenterol Hepatol 1996; 11: 646-51.
23. Zöhrens G, Armbrust T, Meyer Zum Buschenfelde KH, Ramadori G. Interferon-alpha 2a increases serum concentration of hyaluronic acid and type III procollagen aminoterminal propeptide in patients with chronic hepatitis B virus infection. Digest Dis Sci 1994; 39: 2007-13.
24. Murawaki Y, Ikuta Y, Koda M, Nishimura Y, Kawasaki H. Clinical significance of serum hyaluronan in patients with chronic viral liver disease. J Gastroenterol Hepatol 1996; 11: 459-65.